MTOR and nonpapillary renal cell carcinoma: Our results indicated that OSMI-1, an inhibitor of OGT, significantly decreased O-GlcNAcylation in ccRCC cells, as well as the expression levels of UBAP2L and components of the Melk-PI3K-AKT-mTOR signaling pathway (Fig. 9I).